Ventripoint Announces Debt Settlement Agreements

Core Insights - Ventripoint Diagnostics Ltd. has agreed to settle $542,591.50 of debt by issuing 5,425,915 common shares at a price of $0.10 per share [1][2] - The share issuance is intended to preserve cash for business development and is subject to approval by the TSX Venture Exchange [2] Company Overview - Ventripoint is a leader in applying AI to echocardiography, with its VMS products utilizing proprietary knowledge-based reconstruction technology for accurate volumetric cardiac measurements comparable to MRI [4] - The VMS+ product is versatile and compatible with all ultrasound systems, supported by regulatory approvals in the U.S., Europe, and Canada [4]